Novavax (NVAX) Misses Q3 EPS by 40c

Novavax (NASDAQ: NVAX) reported Q3 EPS of ($4.31), $0.40 worse than the analyst estimate of ($3.91). Revenue for the quarter came in at $178.8 million versus the consensus estimate of $334.62 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• XP Inc. (XP) Tops Q2 EPS by 8c
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance